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Abstract 
Background: Helicobacter pylori infection is a common chronic human bacterial infection. Triple- therapy 
regimen containing a proton pump inhibitor, clarithromycin, and either amoxicillin or metronidazole is 
commonly used as first-line treatment for its eradication. However, it may not provide the acceptable eradication 
rate. The present study was designed to evaluated efficacy of low dose furazolidone with amoxicillin and 
omeprazole for eradication of H- pylori. 
Materials and Methods: One hundred twenty patients with non- ulcer dyspepsia or peptic ulcer confirmed by 
upper GI endoscopy, plus H- pylori infection confirmed by rapid urease test were included in the study. They 
were randomly divided into two groups, and then received clarithromycin, amoxicillin, and omeprazole, or 
furazolidone (100 mg PO bid), amoxicillin, and omeprazole. They were evaluated using urea breath test at the 
end of the study. 
Findings: The eradication rates were 57.6% and 78.8% in clarithromycin and furazolidone groups, respectively. 
Their difference was statistically significant (P value 0.013). No side effect was seen in the furazolidone group. 
Conclusion: Low dose furazolidone rather than clarithromycin can be used as low- cost and effective drug for 
eradication of H- pylori, in combination with amoxicillin and omeprazole. 
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1. Introduction 
Helicobacter pylori (H- pylori) infection is one of the most common chronic human bacterial infections. It is 
responsible for the most frequent and persistent bacterial infections worldwide. H- pylori infection affects nearly 
half of the world’s population (Garza-González, Perez-Perez, Maldonado-Garza, & Bosques-Padilla, 2014). The 
consequences of the infection are chronic gastritis, gastric and duodenal ulcers, gastric cancer, and primary 
gastric lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma). Eradication of H- pylori may 
cure dyspepsia, peptic ulcer disease, and MALT lymphoma (Peedikayi, AlSohaibani, & Alkhenizan, 2014). 
The treatment programs for the implementation of H- pylori eradication therapy should be based on patient 
compliance, antibiotic medication history, and local antibiotic resistance. The common treatment programs 
included triple therapy, quadruple therapy (containing bismuth), sequential therapy, concomitant therapy with 
proton pump inhibitor (PPI) and amoxicillin, clarithromycin and metronidazole for 10–14 days (Rongli & Liya, 
2014). However, H- pylori eradication treatments following these regimens produce cure rates lower than 80%, 
mainly due to an increase in clarithromycin resistance (Chuah, Tsay, Hsu, & Wu, 2011; Ayala, 
Escobedo-Hinojosa, de la Cruz-Herrera, & Romero, 2014). Multiple bacterial factors are influencing eradication 
therapy success rate, with the development of resistance to antibiotics as the most important. Moreover, poor 
patient compliance due to adverse reactions to the medications, the cost of the drugs, or patient difficulties 
complying with the therapy regimen should not be ignored (Song &Ang, 2014). Recently, the efficacy of triple 
therapy decreased globally due to the increased rate of clarithromycin resistance (Talebi Bezmin Abadi, 2014). A 
recent multicenter study showed that resistance rates have been 17.5% for clarithromycin, 14.1% for 
levofloxacin and 34.9% for metronidazol (Kanizaj & Kunac, 2014). So, investigation for other treatment 
regimens has been noticed (Federico, Gravina, Miranda, Loguercio, & Romano, 2014).  
www.ccsenet.org/gjhs Global Journal of Health Science Vol. 7, No. 1; 2015 
236 
 
Furazolidone is a synthetic nitrofuran derivative with bactericidal or bacteriostatic activity against Gram-positive 
and Gram-negative bacteria. It is well absorbed in the intestine with no tissue accumulation. It has been used for 
eradication of H- pylori in earlier studies in combination with other drugs as second or third line therapy (Isakov, 
Domareva, Koudryavtseva, Maev, & Ganskaya, 2002; Eisig et al., 2005; Machado, da Silva, & Viriato, 2008; 
Cheng & Hu, 2009). One of the great impediments regarding the use of furazolidone is its association with 
significant adverse effects (Isakov et al., 2002; Eisig et al., 2005; Eisig et al., 2009). Then, can we use lower dose 
of the drug to avoid its side effects?  
The present study was designed to evaluate efficacy of a lower dose of furazolidone in eradication of H- pylori 
as first-line therapy in patients with peptic ulcer disease and non-ulcer dyspepsia compared to clarithromycin. 
2. Materials & Methods 
2.1 Materials Studied 
One hundred twenty patients older than 15 years were chosen from endoscopy ward of a teaching hospital in 
Qazvin City, Iran for the study. They were referred for upper GI endoscopy by their treating physicians due to GI 
symptoms. Rapid urease test had been performed for them and were positive. Their endoscopic diagnosis was 
peptic ulcer disease or non-ulcer dyspepsia. Any patient with past history of previous GI surgery, cigarette 
smoking, pregnancy, hemolytic anemia, or need for administration of any antibiotic or non-steroidal 
anti-inflammatory drugs were excluded from the study. 
2.2 Methods 
The patients were randomly divided into two groups. The first group received clarithromycin 500 mg PO bid and 
amoxicillin 500 mg PO bid for 2 weeks, in addition to omeprazole 20 mg PO bid for 6-8 weeks. The second 
group was given furazolidone 100 mg PO bid and amoxicillin 500 mg PO bid for 2 weeks, as well as omeprazole 
20 mg PO bid for 6-8 weeks. 
The patients were evaluated for eradication of H- pylori 2 weeks after ending of the study by urea breath test 
(UBT). 
The study had been approved by local ethical committee of Qazvin's university of medical sciences. The patients 
provided written informed consent for participation in the study. 
The collected data were analyzed by T-test and chi-square test using SPSS statistical software version 16.0.  
3. Results 
Fifty nine patients were allocated to the first group and sixty one patients were assigned into the second group. 
All the patients ended their instructed drug regimen and no loss of follow up were seen. Moreover, no disturbing 
adverse effects of the drugs were reported by the patients. The general characteristics of the groups were 
demonstrated in Table 1. 
 
Table 1. The general characteristics of the studied groups 
Age (years)  Group 1 Group 2 P value 
41.51±12.11 41.33±13.52 Not significant 
Gender male 25 25 Not significant 
female 34 36 
Level of education High school 41 36 Not significant 
Bachelor degree 18 21 
Higher than bachelor degree 0 4 
Symptoms Epigastric burning pain 6 7 Not significant 
Abdominal pain 32 33 
Epigastric fullness  21 21 
Diagnosis Non-ulcer dyspepsia (NUD) 48 42 Not significant 
Peptic ulcer (PU) 11 19 
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Result of urea breath test 2 weeks after the study was shown in table 2. The results were also evaluated between 
the groups according to the diagnosis 
 
Table 2. Result of urea breath test in the studied groups 2 weeks after the study 
 Group 1 Group 2 P value 
NUD PU total NUD PU total 
UBT negative 27(56.3%) 7(63.6%) 34(57.6%) 33(78.6%) 15(78.9%) 48(78.7%) 0.013 Odds ratio 2.715 
(95% CI: 1.218-6.050) UBT positive 21(43.7%) 4(36.4%) 25(42.4%) 9(21.4%) 4(21.1%) 13(21.3%) 
 
4. Discussion 
The present study suggested that furazolidone can be use as first line drug for eradication of H- pylori instead of 
clarithromycin. We reached the eradication rate near 80%, even though we have used low dose furazolidone (100 
mg per dose rather than 200 mg per dose that had been used in earlier similar studies). 
There are many schemes for treating H- pylori infection. However, an optimal treatment has not been defined, 
and there is not a single antibiotic treatment that can eradicate it (Garza-González et al., 2014). Undeniably, the 
H- pylori treatment story is far from complete. The current sharp fall in eradication rate of therapy has sobered to 
be careful in this topic (Talebi Bezmin Abadi, 2014). The effectiveness of the most commonly used therapies has 
been increasingly compromised by the rapid emergence of antibiotic-resistant strains of H- pylori and by poor 
adherence to treatment by patients (Garza-González et al., 2014). The reason for the decrease in the efficacy of 
standard triple therapy is mainly due to the increase in the resistance against clarithromycin (lee & Kim, 2014). 
In general, several international guidelines for treating patients diagnosed with H- pylori infections are consistent 
with the use of triple therapy as the first-line treatment. This treatment consists of the administration of a proton 
pump inhibitor (PPI), clarithromycin, and amoxicillin for 7-14 d (Ayala G et al., 2014). However, recent reports 
indicate that this regimen does not achieve acceptable eradication rate. The most important cause for the reduced 
success of standard triple therapy is the increasing rate of H- pylori clarithromycin/ metronidazole resistance 
(Peedikayi et al., 2014). The contributory factors to treatment failure are multidimensional and complex. Host 
genetic factors, H- pylori virulent factors, antibiotic resistant H- pylori strains, smoking habits, compliance to 
therapy and duration of therapy all affect the treatment outcome (Song & Ang, 2014). Clinical experience in Iran 
has demonstrated that the eradication rate of H- pylori with the standard therapy is much lower than the rate 
reported from western and developed countries, and a high rate of metronidazole resistance (37%) and an 
increasing rate of resistance to clarithromycin have emerged (Ghadir et al., 2011). So, research for more suitable 
therapy necessitates. 
Eisig and his colleagues (2005) have used quadruple therapy consisted of furazolidone, tetracycline, omeprazole, 
and bismuth for 7 days in patients with previous treatment failure. They have reported 67% eradication rate. He 
has studied another drug combination with furazolidone, levofloxacin, and lansoprazole in his later research, 
again in patients with previous treatment failure (Eisig et al., 2009). He has reported 88% eradication rate with 
this regimen. Isakov and his coworkers (2002) have evaluated efficacy of furazolidone, tetracycline, and 
omeprazole in eradication of H- pylori in patients with first-line treatment failure. They reached to 90% 
eradication rate. Combination of furazolidone and amoxicillin plus omeprazole has been evaluated by Felga and 
his collaborators (2008) in patients with first-line treatment failure. They have reported 68% eradication rate. 
The above mentioned studies have been performed on patients with previous treatment failure. All of them had 
used furazolidone 200 mg twice a day for 1 to 2 weeks. However, the main concern regarding use of 
furazolidone is the adverse effects observed, especially among individuals who do not adhere to the dietary 
restrictions recommended, since this drug belongs to the group of the MAO inhibitors. So, we used half of this 
dose in our study. We wanted to clarify the eradication rate with this dosage of the drug. This dosage has been 
used by Cheng and Hu (2009) in combination with amoxicillin, bismuth, and rebaprazole with the reported 82% 
eradication rate. The present study reached to the nearly same rate, though we did not used bismuth, and used 
omeprazole instead of rebaprazole. The eradication rate in the present study is comparable to studies of Eisig 
(2009), Isakov (2002), and Felga (2008); despite the fact that we had used half-dose furazolidone in combination 
with the low cost drugs (amoxicillin and omeprazole). The eradication rate was higher than that of the higher 
cost drug, clarithromycin.  
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5. Conclusion 
The present study suggests that low- dose furazolidone can effectively be used for treatment of H- pylori to 
prevent the side effects of the drug. 
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